High glucose enhances thrombin responses via protease-activated receptor-4 in human vascular smooth muscle cells

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 31, Issue 3, 2011, Pages 624-633

  Dangwal, Seema ^a   Rauch, Bernhard H ^a   Gensch, Thomas ^b   Dai, Luru ^c   Bretschneider, Ellen ^d   Vogelaar, Christina Francisca ^a   Schrör, Karsten ^a   Rosenkranz, Anke C ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b FORSCHUNGSZENTRUM JÜLICH   (Germany)

^c NATIONAL CENTER FOR NANOSCIENCE AND TECHNOLOGY   (China)

^d FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

diabetes mellitus; protease activated receptors; thrombin; vascular muscle

Indexed keywords

CALCIUM; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN KINASE C; PROTEIN KINASE C BETA; PROTEIN KINASE C DELTA; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 3; PROTEINASE ACTIVATED RECEPTOR 4; THROMBIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CELL MIGRATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; PRIORITY JOURNAL; PROTEIN BINDING; REGULATORY MECHANISM; SMOOTH MUSCLE FIBER; TRANSLOCATION LINE; VASCULAR SMOOTH MUSCLE;

BINDING SITES; CALCIUM; CALCIUM SIGNALING; CELL MOVEMENT; CELLS, CULTURED; CHROMATIN IMMUNOPRECIPITATION; DIABETIC ANGIOPATHIES; GLUCOSE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NF-KAPPA B; PROMOTER REGIONS, GENETIC; PROTEIN KINASE C; PROTEIN KINASE C-DELTA; PROTEIN KINASE INHIBITORS; RECEPTOR, PAR-1; RECEPTORS, THROMBIN; RNA INTERFERENCE; RNA, MESSENGER; THROMBIN; TIME FACTORS; TRANSCRIPTIONAL ACTIVATION; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 79952188205     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.110.219105     Document Type: Article

References (30)

1. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287: 2570-2581. (Pubitemid 34517204)
2. Ahmed JM, Hong MK, Mehran R, Dangas G, Mintz GS, Pichard AD, Satler LF, Kent KM, Wu H, Stone GW, Leon MB. Influence of diabetes mellitus on early and late clinical outcomes in saphenous vein graft stenting. J Am Coll Cardiol. 2000;36:1186-1193.
3. Srivastava AK. High glucose-induced activation of protein kinase signaling pathways in vascular smooth muscle cells: a potential role in the pathogenesis of vascular dysfunction in diabetes (review). Int J Mol Med. 2002;9:85-89.
4. Forrester JS, Fishbein M, Helfant R, Fagin J. A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies. J Am Coll Cardiol. 1991;17:758-769.
5. Undas A, Wiek I, Stepien E, Zmudka K, Tracz W. Hyperglycemia is associated with enhanced thrombin formation, platelet activation, and fibrin clot resistance to lysis in patients with acute coronary syndrome. Diabetes Care. 2008;31:1590-1595.
6. Brummel KE, Paradis SG, Butenas S, Mann KG. Thrombin functions during tissue factor-induced blood coagulation. Blood. 2002;100: 148-152. (Pubitemid 35177440)
7. Ghigliotti G, Waissbluth AR, Speidel C, Abendschein DR, Eisenberg PR. Prolonged activation of prothrombin on the vascular wall after arterial injury. Arterioscler Thromb Vasc Biol. 1998;18:250-257. (Pubitemid 28277602)
8. Martorell L, Martinez-Gonzalez J, Rodriguez C, Gentile M, Calvayrac O, Badimon L. Thrombin and protease-activated receptors (PARs) in atherothrombosis. Thromb Haemost. 2008;99:305-315. (Pubitemid 351230960)
9. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature. 2000;407:258-264.
10. Ahn HS, Chackalamannil S, Boykow G, Graziano MP, Foster C. Development of proteinase-activated receptor 1 antagonists as therapeutic agents for thrombosis, restenosis and inflammatory diseases. Curr Pharm Design. 2003;9:2349-2365. (Pubitemid 37236356)
11. Stouffer GA, Schmedtje JF, Gulba D, Huber K, Bode C, Aaron J, Runge MS. Restenosis following percutaneous revascularization-the potential role of thrombin and the thrombin receptor. Ann Hematol. 1996;73: S39-S41. (Pubitemid 26325364)
12. Kahn ML, Zheng YW, Huang W, Bigornia V, Zeng D, Moff S, Farese RV Jr, Tam C, Coughlin SR. A dual thrombin receptor system for platelet activation. Nature. 1998;394:690-694. (Pubitemid 28389797)
13. Bretschneider E, Kaufmann R, Braun M, Nowak G, Glusa E, Schror K. Evidence for functionally active protease-activated receptor-4 (PAR-4) in human vascular smooth muscle cells. Br J Pharmacol. 2001;132: 1441-1446. (Pubitemid 32281032)
14. Bretschneider E, Spanbroek R, Lotzer K, Habenicht AJ, Schror K. Evidence for functionally active protease-activated receptor-3 (PAR-3) in human vascular smooth muscle cells. Thromb Haemost. 2003;90: 704-709. (Pubitemid 37287639)
15. Fallier-Becker P, Rupp J, Fingerle J, E B. Smooth muscle cells from rabbit aorta. In: Piper H, ed. Cell Culture Techniques in Heart and Vessel Research. Berlin/Heidelberg/New York: Springer Verlag; 1990:247-270.
16. Rosenkranz AC, Rauch BH, Freidel K, Schror K. Regulation of protease-activated receptor-1 by vasodilatory prostaglandins via NFAT. Cardiovasc Res. 2009;83:778-784.
17. Rauch BH, Weber A, Braun M, Zimmermann N, Schrör K. PDGFinduced Akt phosphorylation does not activate NF-kappa B in human vascular smooth muscle cells and fibroblasts. FEBS Lett. 2000;481:3-7. (Pubitemid 30662367)
18. McLaughlin JN, Patterson MM, Malik AB. Protease-activated receptor-3 (PAR3) regulates PAR1 signaling by receptor dimerization. Proc Natl Acad Sci U S A. 2007;104:5662-5667. (Pubitemid 47175737)
19. Strande JL, Hsu A, Su J, Fu X, Gross GJ, Baker JE. Inhibiting proteaseactivated receptor 4 limits myocardial ischemia/reperfusion injury in rat hearts by unmasking adenosine signaling. J Pharmacol Exp Ther. 2008; 324:1045-1054. (Pubitemid 351397828)
20. Ritchie E, Saka M, Mackenzie C, Drummond R, Wheeler-Jones C, Kanke T, Plevin R. Cytokine upregulation of proteinase-activated-receptors 2 and 4 expression mediated by p38 MAP kinase and inhibitory kappa B kinase beta in human endothelial cells. Br J Pharmacol. 2007;150: 1044-1054. (Pubitemid 46625087)
21. Hamilton JR, Frauman AG, Cocks TM. Increased expression of proteaseactivated receptor-2 (PAR2) and PAR4 in human coronary artery by inflammatory stimuli unveils endothelium-dependent relaxations to PAR2 and PAR4 agonists. Circ Res. 2001;89:92-98. (Pubitemid 34135497)
22. Rudijanto A. The role of vascular smooth muscle cells on the pathogenesis of atherosclerosis. Acta Med Indones. 2007;39:86-93.
23. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999; 340:115-126.
24. Pickup JC, Chusney GD, Thomas SM, Burt D. Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes. Life Sci. 2000;67:291-300. (Pubitemid 30413937)
25. Scheen AJ, Warzee F. Diabetes is still a risk factor for restenosis after drug-eluting stent in coronary arteries. Diabetes Care. 2004;27: 1840-1841. (Pubitemid 38857477)
26. -/-mice. Atherosclerosis. 2009;205:427-432.
27. Itoh H, Yamamura S, Ware JA, Zhuang S, Mii S, Liu B, Kent KC. Differential effects of protein kinase C on human vascular smooth muscle cell proliferation and migration. Am J Physiol. 2001;281:H359-H370.
28. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes. 1998;47:859-866. (Pubitemid 28255657)
29. Wilson SH, Best PJ, Edwards WD, Holmes DR Jr, Carlson PJ, Celermajer DS, Lerman A. Nuclear factor-kappaB immunoreactivity is present in human coronary plaque and enhanced in patients with unstable angina pectoris. Atherosclerosis. 2002;160:147-153. (Pubitemid 34082720)
30. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-κB activity. Ann Rev Immunol. 2000;18:621-663. (Pubitemid 30365393)